$13.25
+0.20 (+1.53%)
Open$12.92
Previous Close$13.05
Day High$13.34
Day Low$12.92
52W High$15.35
52W Low$6.62
Volume—
Avg Volume706.6K
Market Cap1.25B
P/E Ratio15.87
EPS$0.71
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+375.5% upside
Current
$13.25
$13.25
Target
$63.01
$63.01
$47.40
$63.01 avg
$83.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 99.16M | 57.56M | 298.22M |
| Net Income | -139,143,661 | -72,693,617 | -30,982,952 |
| Profit Margin | -140.3% | -133.3% | -10.4% |
| EBITDA | -128,746,349 | -70,998,451 | -39,492,333 |
| Free Cash Flow | — | — | -35,501,473 |
| Rev Growth | +72.3% | +72.3% | -0.7% |
| Debt/Equity | 1.08 | 1.08 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.55 | +0.40% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $409.22 | +4.08% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $519.07 | +1.63% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $811.01 | +1.61% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $253.98 | +3.95% | 40.0 | 32.33B |